MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$3.88
-0.09 (-2.27%)
Open$3.98
Previous Close$3.97
Day High$3.99
Day Low$3.79
52W High$7.97
52W Low$3.03
Volume—
Avg Volume2.08M
Market Cap566.19M
P/E Ratio90.75
EPS$0.04
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+522.4% upside
Current
$3.88
$3.88
Target
$24.15
$24.15
$19.42
$24.15 avg
$35.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 404.88M | 348.85M | 190.63M |
| Net Income | 46.98M | 36.43M | 27.70M |
| Profit Margin | 11.6% | 11.0% | 14.5% |
| EBITDA | 63.15M | 51.69M | 34.17M |
| Free Cash Flow | — | — | 29.04M |
| Rev Growth | +16.1% | +16.1% | +8.9% |
| Debt/Equity | 0.07 | 0.07 | 0.66 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |